Plain-English translation of NCT06802081 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a once-weekly injection, can help improve atrial fibrillation (a condition where your heart beats irregularly) by helping you lose weight. The study involves 100 people with obesity and atrial fibrillation who will receive either the medication or a placebo injection over 12 months, with researchers carefully monitoring how their heart rhythm improves.
Extra weight is a major risk factor for atrial fibrillation, and weight loss has been shown to help control this condition. Researchers want to see if this medication—which helps people lose weight—can also reduce irregular heartbeat symptoms and improve quality of life for patients dealing with both conditions.
You likely qualify if…
You likely don't qualify if…
You will receive weekly injections—either the study medication or placebo—starting with a small dose that gradually increases over 12 weeks. Throughout the year, you'll wear a heart monitor device periodically to measure your heart rhythm, attend regular clinic visits, and receive standard heart health counseling including nutrition and lifestyle advice. The study team will assess how your atrial fibrillation symptoms and heart rhythm change over the 12-month period.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States